First published data evaluating gene-editing treatment in children ages 5-11 with inherited blood disorders highlights the potential for earlier intervention before cumulative injury

HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia.